Radiopharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Radiopharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Radiopharmaceutical Today - Breaking & Trending Today

Jubilant Pharmova sells stake in Sofie Biosciences for $139.4 million

JPL holds a 25.8% stake in Sofie Biosciences, which it acquired through its Singapore-based subsidiary Jubilant Pharma in November 2020 for $25 million. ....

Jubilant Pharmova Ltd , Sofie Biosciences , Jubilant Pharma , Trilantic Capital Partners , Jubilant Pharmova , Private Equity ,

Johns Hopkins Medicine Lab Awarded $15 Million to Study Targeted Radiation for Treatment-Resistant Cancers

The Radiopharmaceutical Therapy and Dosimetry Lab at Johns Hopkins Medicine, headed by George Sgouros, Ph.D., has been awarded a $15 million grant, to be dispersed over the next five years, from the National Cancer Institute at the National Institutes of Health. They will use these funds to investigate a type of radiation therapy for hard-to-treat cancers. The award will fund several research projects, all of which will investigate a promising cancer treatment known as alpha-particle em. ....

George Sgouros , Johns Hopkins University School Of Medicine , National Institutes Of Health , Dosimetry Lab At Johns Hopkins Medicine , Johns Hopkins Medicine Lab , National Cancer Institute , Johns Hopkins Medicine Lab Awarded , Study Targeted Radiation , Johns Hopkins , Radiopharmaceutical Therapy , Dosimetry Lab , Johns Hopkins Medicine , National Institutes , Johns Hopkins University School , Press Release Image , Ard To Treat , Alpha Particle , Press Release , Ews Release ,

Bristol Myers to buy cancer therapy company in $4.1 billion deal

Bristol Myers Squibb on Tuesday announced a deal to acquire RayzeBio in an effort to expand the drugmaker’s cancer treatment offerings. The acquisition was for a total equity value of about $4.1 billion, at $62.50 per share. RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company, has several cancer treatments under development, specifically ones targeting the treatment… ....

Samit Hirawat , Christopher Boerner , Bristol Myers Squibb , Myers Squibb , President Ken Song , Cancer Treatment , Solid Tumors , Neuroendocrine Tumors , Drug Development , Small Cell Lung Cancer ,

Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint

Despite achieving its Phase 3 study's main goal, the results for Point Biopharma's therapy are short of what Novartis radiopharmaceutical Pluvicto achieved in a similarly designed clinical trial. Nevertheless, the data readout should clear the way for Eli Lilly to complete its $1.4 billion acquisition of Point. ....

Faisal Khurshid , Novartis Pluvicto , Eli Lilly , Point Biopharma Global , Indianapolis Based Point , Leerink Partners , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery , Ealth And Wellness , Mployee Wellness Programs ,